Following on from the myopia news on ACUVUE Abiliti™ Overnight Therapeutic Lenses, the FDA have given Breakthrough Device designation to Essilor Group’s Stellest spectacle lens. This lens aims to correct myopia and slow down its development in children. Myopia found in children is at the most risk of developing into a more serious condition.
The first-year trial results showed that 9 out of 10 children who wore the Essilor Stellest lens had similar or slower eye growth than children without myopia. “The “Breakthrough Device” designation for our Essilor Stellest lens is a great achievement and an illustration of its potential in slowing down the progression of myopia in children. This designation represents an important milestone in our fight against the myopia pandemic,” Norbert Gorny, Chief Operating Officer and Chief Research & Development Officer of Essilor International
James Pickering is our Managing Director and an eye care recruitment expert who has developed an extensive client base and candidate network. He regularly writes articles about industry developments and has received numerous recommendations from industry leaders. You can also connect with James on LinkedIn to stay up to date on the latest eye care news.